The size of the global central nervous system (CNS) therapeutics market will increase USD 18.64 billion between 2017-2022, accelerating at a CAGR of 4% during the forecast period. This growth in market size will be attributed to the rapidly growing geriatric population which is leading to an increase in the number of neurological disease cases. Additionally, there is an increasing prevalence of mental illnesses which is also contributing to the market's growth. In 2017, it was recorded that approximately 20% of the US population suffered from mental disorders.
Several emerging trends are expected to gain traction over the next few years and positively impact the global CNS market. These top trends include the increased adoption of new-generation drugs, advances in technology in treating mental disorders, and the increasing number of CNS awareness programs. The number of awareness programs about CNS diseases continues to rise, for example, March 30th is World Bipolar Day which brings awareness about bipolar disorder and helps to eliminate social stigma. Other insights provided within Technavio’s CNS market reports include:
Within our central nervous system industry research, we provide deep insights into the market landscape, its segments, and their market share. Our central nervous system market segmentation research offerings include:
In addition to the above-mentioned markets, our reports within the CNS industry also provide critical insights on several markets for treatments and procedures such as the deep brain stimulation devices market, bipolar disorder therapeutics market, post-traumatic stress disorder (PTSD) therapeutics market, and migraine drugs market. Further, Technavio’s research reports offer a comprehensive understanding of the market space along with the factors that are impacting the growth patterns in the coming years.
Our market research reports within the central nervous system industry offer a detailed market analysis based on the latest trends and drivers that are anticipated to influence the growth patterns over the coming years. Our market research covers several critical insights within the CNS industry such as:
Our industry analysts critically observe the development taking place in clinical trials CNS and neurological disorders market across the globe. Our pipeline reports cover the entire development phase of the drug ending with the registration of new drugs. For further insights, our CNS & neurological disorders clinical submissions are classified as biosimilars or new molecular entity.